Serum keratan sulfate levels in osteoarthritis patients

M. Barry E Sweet, Angelina Coelho, Christine M. Schnitzler, Thomas J. Schnitzer, Mary Ellen Lenz, Itzhak Jakim, Klaus E. Kuettner, EUGENE J ‐M A Thonar

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


Serum levels of keratan sulfate (KS), measured by an enzyme‐linked immunosorbent–inhibition assay, were found to be significantly higher in 31 patients with hypertrophic osteoarthritis (OA) than those in 41 adults without joint disease. Seventy‐seven percent of patients with OA, but only 12% of control subjects, had serum levels which were more than 1 SD above the mean of the control group. Following replacement of a single osteoarthritic hip joint, serum KS levels decreased, at first, in all patients. Subsequently, the concentration of serum KS progressively increased; 6 months following surgery, KS levels were similar or close to the preoperative levels in virtually all patients. The results suggest that patients with hypertrophic OA may have a generalized imbalance of cartilage proteoglycan metabolism. Measurements of serum KS are likely to prove most useful in studying this particular subset of patients with generalized OA.

Original languageEnglish (US)
Pages (from-to)648-652
Number of pages5
JournalArthritis & Rheumatism
Issue number5
StatePublished - May 1988

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)


Dive into the research topics of 'Serum keratan sulfate levels in osteoarthritis patients'. Together they form a unique fingerprint.

Cite this